Tekla Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Tekla Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-31,594	Closed	-$418K	–	177
2021 Q4	$418K	Sell	31,594 -68,406	-68%	-$1.09M	0.01%	163
2021 Q3	$1.75M	Hold	100,000	–	–	0.06%	139
2021 Q2	$2.4M	Buy	100,000 +50,000	+100%	+$1.31M	0.08%	151
2021 Q1	$1.28M	Buy	+50,000	New	+$1.31M	0.04%	172

Other funds holding KALV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's KALV Position: Q1 2022 in Review

Tekla Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 31,594 shares — an estimated $418K sold.

Tekla Capital Management first reported a position in KALV in Q1 2021 and held it in 4 quarters. The position peaked at $2.4M in Q2 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

Tekla Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Tekla Capital Management sold 31,594 KalVista Pharmaceuticals shares in Q1 2022, an estimated $418K.
Tekla Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Tekla Capital Management's KalVista Pharmaceuticals position peaked at $2.4M in Q2 2021.
89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.